Zimmer Biomet Holdings, INC

Zimmer Biomet Holdings, Inc. has entered into new five-year and 364-day revolving credit agreements totaling $2.75 billion, replacing previous facilities.

Zimmer Biomet shareholders re-elected ten directors and ratified the appointment of PricewaterhouseCoopers LLP at the 2026 annual meeting.

Zimmer Biomet announced an increased share repurchase program, now targeting up to $1 billion in fiscal year 2026, a $250 million rise from previous expectations.

Zimmer Biomet Holdings, Inc. announced the resignation of its Chief Financial Officer, Suketu Upadhyay, effective April 28, 2026, with Paul Stellato appointed as interim CFO.

Zimmer Biomet announced first quarter 2026 net sales of $2.087 billion, a 9.3% increase, and raised its full-year adjusted EPS guidance.

Zimmer Biomet announced robust fourth-quarter and full-year 2025 financial results, exceeding initial commitments, and authorized a new $1.5 billion stock repurchase program.

Zimmer Biomet reported a 9.3% increase in Q1 2026 net sales to $2.09 billion, driven by the Paragon 28 acquisition and strong demand for robotic and surgical technologies.

Zimmer Biomet Holdings, Inc. reported a 9.7% increase in net sales for the third quarter of 2025, driven by strategic acquisitions and market growth, despite a decline in net earnings.

Zimmer Biomet Holdings, Inc. reported a 7% increase in net sales for Q2 2025, driven by acquisitions and market growth, but net earnings significantly declined due to acquisition-related costs and higher interest expenses.

Zimmer Biomet's Q1 2025 net sales rose by 1.1% year-over-year, but the company anticipates lower net earnings for the year due to acquisition and integration costs related to Paragon 28.

Zimmer Biomet's Q3 2024 results show a net sales increase of 4.0% year-over-year, despite operational challenges from a new ERP system implementation.

Zimmer Biomet's Q2 2024 results show a net sales increase but a decrease in net earnings for the six-month period, influenced by restructuring costs and other factors.

Zimmer Biomet's 2024 results show a net sales increase of 3.8% and the company plans to acquire Paragon 28, Inc.

Zimmer Biomet has updated its executive change in control severance agreements to provide for either a reduction in payments to avoid excise tax or full payment, whichever results in a better after-tax outcome for the executive.

Kevin R Thornal, Grp Pres-Global Business of Zimmer Biomet Holdings, Inc., reported multiple transactions in common stock on August 1, 2026.

Maria Teresa Hilado, a Director at Zimmer Biomet Holdings, Inc., reported transactions involving phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.

Zimmer Biomet Holdings, Inc. Director Devdatt Kurdikar reported the accrual of 180.323 phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.

Robert Hagemann, a Director at Zimmer Biomet Holdings, Inc., has reported transactions related to phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.

Arthur J. Higgins, a Director at Zimmer Biomet Holdings, Inc., reported the acquisition of phantom stock units under the company's Deferred Compensation Plan for Non-Employee Directors.

Director Sreelakshmi Kolli of Zimmer Biomet Holdings, Inc. has reported transactions related to phantom stock units, indicating changes in beneficial ownership.

Zimmer Biomet Holdings, Inc. filed its definitive proxy statement for the 2026 annual meeting, outlining strong 2025 financial performance, executive compensation, and board recommendations on key governance matters.

Zimmer Biomet Holdings, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 10, 2024, outlining key voting items and access to proxy materials.

Zimmer Biomet releases its proxy statement, outlining key proposals for the upcoming 2025 annual meeting, including director elections, auditor ratification, and executive compensation.

Zimmer Biomet Holdings, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 10, 2024, outlining key voting items including the election of directors, ratification of the independent auditor, executive compensation, and approval of the amended Employee Stock Purchase Plan.

Zimmer Biomet's proxy statement details the company's corporate governance framework, executive compensation practices, and proposals for the upcoming annual shareholder meeting.

Zimmer Biomet Holdings, Inc. and its subsidiary, Honey Badger Merger Sub, Inc., have entered into a definitive agreement to acquire Monogram Technologies Inc. for a combination of cash and contingent value rights, valuing common stock at up to $16.41 per share.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.1% of Zimmer Biomet Holdings Inc. common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.54% beneficial ownership stake in Zimmer Biomet Holdings Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Zimmer Biomet Holdings Inc. following an internal corporate realignment.

Dodge & Cox, an investment adviser, has reported an increased passive beneficial ownership stake of 11.2% in Zimmer Biomet Holdings, Inc. as of June 30, 2025.

Investment adviser Dodge & Cox has filed an amended Schedule 13G, disclosing a 10.2% beneficial ownership stake in Zimmer Biomet Holdings, Inc. as of April 30, 2025.

BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in Zimmer Biomet Holdings Inc. as of March 31, 2025, held for ordinary course of business purposes.